Recreation

Syndicate content
Contains the last 10 releases
Updated: 16 hours 42 min ago

LiveWell Colorado’s HEAL Cities & Towns Campaign Reaches 50 Municipalities

24 May 2017 - 10:00am

Denver, Colorado, May 24, 2017 (GLOBE NEWSWIRE) -- With tensions rising around health care access in the United States, it’s easy to get discouraged. Yet here in Colorado, there’s a growing movement for healthy change that is helping advance healthy eating and active living (HEAL) policies in communities across the state. Since 2013, LiveWell Colorado’s HEAL Cities & Towns Campaign has worked with municipalities to adopt and implement more than 100 policies and infrastructure investments that increase access to biking, walking, recreation, healthy food, and healthy workplaces—attributes that make communities healthier and more economically successful.

Colorado is one of five states in the national HEAL Cities Campaign founded and funded by Kaiser Permanente. The Colorado Campaign is a partnership between the Colorado Municipal League and LiveWell Colorado, a nonprofit working to increase access to healthy eating and active living by removing barriers that inequitably and disproportionately affect low-income communities and people of color. The Campaign provides free training, tools, and support to help municipal leaders adopt and implement policies in three key areas: active community, healthy food access, and healthy workplace. Since its launch four years ago, the HEAL Cities & Towns Campaign has spread to urban, suburban, and rural communities in every region of Colorado.

With the addition of Sterling and Timnath earlier this month, LiveWell Colorado reached a major milestone—50 participating HEAL municipalities. This means the Campaign is now reaching more than half of our state's total population. “Cities all over the state are doing amazing work and it varies from place to place, as each municipality has its own unique attributes and challenges,” says Julie George, LiveWell Colorado’s HEAL Cities & Towns Campaign Director. “I love La Junta’s plan to install signage at the train stop, informing passengers about where and how close Main Street is. The signs will encourage them to take a short walk, patronize the local businesses, and enjoy a bit of La Junta during their stop. And in Cortez, they’ve changed zoning to allow vegetable gardens in their right of ways and then tied the care and upkeep of these gardens to their summer program for kids. The examples go on and on.”

While the Campaign is made to be flexible in order to work with all municipalities, LiveWell has also placed a particular focus on reaching communities with high poverty levels, where residents are more likely to experience socioeconomic and environmental disadvantages that contribute to poor health. For example, with 19 percent of its residents living below the poverty level, Commerce City faces a number of challenges from homelessness to economic and food insecurity. “Focusing on health can be a real challenge, especially for those in our community who are struggling to make ends meet,” says City Manager Brian McBroom.

Since joining the HEAL Cities & Towns Campaign in 2013, Commerce City has made great strides to improve quality of life for its residents. “The city has put many of the Campaign’s tenets to use by enacting policies that have resulted in new parks and recreational spaces, an enhanced network of local food pantries, and Complete Streets strategies,” says McBroom. In June 2016, Commerce City became the first municipality to reach Elite status—the highest of four levels in the Campaign. Elite cities are those that have adopted five or more HEAL policies.

Arvada also joined the ranks of Elite cities in October 2016. “Through HEAL Cities & Towns, the city of Arvada has received critical guidance, particularly on ways to increase urban agriculture and healthy food access,” says City Manager Mark Deven. Arvada also secured one of seven HEAL Cities & Towns mini-grants in 2016, which provided funds for the city to conduct a healthy food assessment. “This valuable effort would not be possible without the Campaign’s support, and will go a long way toward helping us reach our goals for creating a healthy, vibrant community,” Deven says.  

Colorado Springs, the second-largest city in the state, recently achieved Fit status, the third of four levels in the Campaign. “Since becoming a HEAL city in 2014, Colorado Springs has moved several policies forward and embraced the importance of providing a healthy environment for our residents,” says President Pro Tempore Tem Jill Gaebler. “We formed a Food Policy Advisory Board and are working hard to increase access to healthy food, and have also furthered our active transportation goals by embracing the Complete Streets model.”

 “We are grateful to work with so many extraordinary partners around the state, including the Colorado Department of Public Health and Environment as well as the Colorado Municipal League and their membership,” says LiveWell President and CEO, Gabriel Guillaume.  “Our overall aim is to remove barriers that create health disparities and to support residents with the tools needed to improve the infrastructure that makes physical activity and healthy food options possible. This Campaign leverages the value so many put on equitable access to healthy behaviors and as a result has been an effective method for achieving that goal.”

All 50 Colorado HEAL Cities & Towns Partner Cities (by level)

ELITEBrushManitou SpringsArvadaBuena VistaMillikenCommerce CityCarbondaleMontroseCortezCedaredgeNederlandLakewoodCentennialNew CastleNorthglennDenverOak CreekPuebloDurangoRifle EdgewaterSteamboatFITEnglewoodSpringsColorado SpringsFort CollinsSterlingGoldenFrederickTimnathLittletonGlenwood SpringsThorntonSalidaGreeleyVailSheridanKiowaWalsenburgLa JuntaLafayetteWheat Ridge Lamar ACTIVELeadvilleEAGERAuroraLone TreeSaguacheBennettLongmontYuma  Mountain View

 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dfc9ddff-2387-40ae-bcdb-8ee2719a8ca3

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/24f496ea-5643-46b2-9c4c-1e54a2480339

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1878fe2c-a6b8-428f-ba41-b92cc2302de1

CONTACT: Angelle Fouther LiveWell Colorado 720-573-3622 angellefouther@livewellcolorado.org
Categories: State

Marijuana Company Kaya Holdings 10-Q and 8-K filings Detail $5.8 Million Additional Financing Agreement and Increased Cash Position, Additional OLCC Marijuana Retailer Licenses  

23 May 2017 - 7:57am

FORT LAUDERDALE, Fla., May 23, 2017 (GLOBE NEWSWIRE) -- Kaya Holdings, Inc. (OTCQB:KAYS), filed its Quarterly report and a 8-K after close of market yesterday afternoon. Developments include a $5.8 mm financing agreement reached with the Cayman Venture Capital Fund (an institutional investor that has previously furnished KAYS with approximately $3.3mm in financing), as well as receipt of its third Marijuana Retailer and Delivery Licenses from the Oregon Liquor Control Commission (“OLCC”).

“KAYS is pleased to announce that it has received its OLCC and City recreational marijuana retail licenses for its Portland store where it has resumed recreational sales. This brings us to 3 fully-licensed and operational Kaya Shack™ OLCC retail marijuana stores, with the 4th expected to be completed over the next 60 days,” reported Kaya Holdings CEO Craig Frank. “Additionally, we have ordered more Fiat 500 cars to build our Kaya Car™ Home Delivery Service which we intend to launch contemporaneously with a grand opening celebration for all four OLCC-Licensed Kaya Shack™ retail marijuana stores.”

“While sales were down approximately $100,000 for Q-1 2017 versus the same period in 2016 (as we were only able to conduct recreational sales at one outlet as compared to two outlets in the same period in 2016), our cash position has increased by over 700% to in excess of $1.2mm as of the close of Q-1, for the same relevant periods,” continued Frank. “We are excited to secure this additional funding and believe it provides us with the resources necessary to develop more Kaya Shack™ store locations, construct a large scale state-of-the-art facility for Kaya Farms™, begin seeking worthwhile opportunities in other states, and introduce products and innovations that continue to define Kaya as a concept pioneer in the cannabis sector.”

About Kaya Holdings, Inc. (KAYS)
Kaya Holdings, Inc. (OTCQB:KAYS) owns and operates Kaya Shack™ legal marijuana dispensaries in Oregon as well as grow and manufacturing operations, which produce, distribute and/or sell premium legal cannabis products under the Company’s own brands, including flower, concentrates, and cannabis-infused baked goods and candies.  KAYS is the first publicly-traded U.S. company to own and operate legal marijuana dispensaries and a vertically integrated legal cannabis grow and manufacturing operation.

Important Disclosure
KAYS is planning execution of its stated business objectives in accordance with current understanding of State and Local Laws and Federal Enforcement Policies and Priorities as it relates to Marijuana (as outlined in the Justice Department's Cole Memo dated August 29, 2013), and plan to proceed cautiously with respect to legal and compliance issues. Potential investors and shareholders are cautioned that the Company will obtain advice of counsel prior to actualizing any portion of its business plan (including but not limited to license applications for the cultivation, distribution or sale of marijuana products, engaging in said activities or acquiring existing cannabis production/sales operations). Advice of counsel with regard to specific activities of KAYS, Federal, State or Local legal action or changes in Federal Government Policy and/or State and Local Laws may adversely affect business operations and shareholder value.

Forward-Looking Statements
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For more information please review the latest 8-K and Quarterly filings available at www.sec.gov, email info@kayaholdings.com, call 561-210-5784 or visit www.kayaholdings.com and sign up for investor updates.

Categories: State

Marijuana Company Kaya Holdings 10-Q and 8-K filings Detail $5.8 Million Additional Financing Agreement and Increased Cash Position, Additional OLCC Marijuana Retailer Licenses  

23 May 2017 - 7:57am

FORT LAUDERDALE, Fla., May 23, 2017 (GLOBE NEWSWIRE) -- Kaya Holdings, Inc. (OTCQB:KAYS), filed its Quarterly report and a 8-K after close of market yesterday afternoon. Developments include a $5.8 mm financing agreement reached with the Cayman Venture Capital Fund (an institutional investor that has previously furnished KAYS with approximately $3.3mm in financing), as well as receipt of its third Marijuana Retailer and Delivery Licenses from the Oregon Liquor Control Commission (“OLCC”).

“KAYS is pleased to announce that it has received its OLCC and City recreational marijuana retail licenses for its Portland store where it has resumed recreational sales. This brings us to 3 fully-licensed and operational Kaya Shack™ OLCC retail marijuana stores, with the 4th expected to be completed over the next 60 days,” reported Kaya Holdings CEO Craig Frank. “Additionally, we have ordered more Fiat 500 cars to build our Kaya Car™ Home Delivery Service which we intend to launch contemporaneously with a grand opening celebration for all four OLCC-Licensed Kaya Shack™ retail marijuana stores.”

“While sales were down approximately $100,000 for Q-1 2017 versus the same period in 2016 (as we were only able to conduct recreational sales at one outlet as compared to two outlets in the same period in 2016), our cash position has increased by over 700% to in excess of $1.2mm as of the close of Q-1, for the same relevant periods,” continued Frank. “We are excited to secure this additional funding and believe it provides us with the resources necessary to develop more Kaya Shack™ store locations, construct a large scale state-of-the-art facility for Kaya Farms™, begin seeking worthwhile opportunities in other states, and introduce products and innovations that continue to define Kaya as a concept pioneer in the cannabis sector.”

About Kaya Holdings, Inc. (KAYS)
Kaya Holdings, Inc. (OTCQB:KAYS) owns and operates Kaya Shack™ legal marijuana dispensaries in Oregon as well as grow and manufacturing operations, which produce, distribute and/or sell premium legal cannabis products under the Company’s own brands, including flower, concentrates, and cannabis-infused baked goods and candies.  KAYS is the first publicly-traded U.S. company to own and operate legal marijuana dispensaries and a vertically integrated legal cannabis grow and manufacturing operation.

Important Disclosure
KAYS is planning execution of its stated business objectives in accordance with current understanding of State and Local Laws and Federal Enforcement Policies and Priorities as it relates to Marijuana (as outlined in the Justice Department's Cole Memo dated August 29, 2013), and plan to proceed cautiously with respect to legal and compliance issues. Potential investors and shareholders are cautioned that the Company will obtain advice of counsel prior to actualizing any portion of its business plan (including but not limited to license applications for the cultivation, distribution or sale of marijuana products, engaging in said activities or acquiring existing cannabis production/sales operations). Advice of counsel with regard to specific activities of KAYS, Federal, State or Local legal action or changes in Federal Government Policy and/or State and Local Laws may adversely affect business operations and shareholder value.

Forward-Looking Statements
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For more information please review the latest 8-K and Quarterly filings available at www.sec.gov, email info@kayaholdings.com, call 561-210-5784 or visit www.kayaholdings.com and sign up for investor updates.

Categories: State

VPR Brands, LP announces First Quarter 2017 Results

23 May 2017 - 7:30am

FORT LAUDERDALE, Fla., May 23, 2017 (GLOBE NEWSWIRE) -- VPR Brands, LP (OTC PINK:VPRB) has released its first quarter 2017 results of operations. Revenue for first quarter 2017 totaled $786,535 with a gross profit of $275,014 and a gross margin of 34.96%. In comparison, the first quarter 2016 revenue and gross profit was $-0- and $-0-, respectively. The increase is a result of the asset acquisition from Vapor Corp. of its wholesale business.

Cost of sales for the quarter ended March 31, 2017 and 2016 was $511,521 and $-0-, respectively. The increase is a result of the asset acquisition from Vapor Corp. of its wholesale business.

Operating expenses for the quarter ended March 31, 2017 were $598,556 as compared to $61,005 for the quarter ended March 31, 2016. The increase in expenses is due to increased general, selling and administrative costs for the asset acquisition from Vapor Corp. Payroll made up $250,482 of the difference and marketing expense another $162,330. The rest of the difference included travel expenses and professional fees related to the Vapor Corp. asset acquisition. 

Net loss for the quarter ended March 31, 2017 was $(292,294), compared to a net loss of $(61,005) for the quarter ended March 31, 2016. The net loss has increased mainly as the result of the expense related to the increased expenses and interest expense from loans related to the acquisition. 

“The Company has completely shifted its focus to service the cannabis sector and is increasing its investment into our award winning HONEYSTICK brand,” said Kevin Frija, CEO of VPR Brands, LP. "We’re excited about our new trajectory and believe that our focus on the HONEYSTICK brand will lead to increased sales of our branded products, which should translate into increased margins and ultimately, profitability."

"The first quarter was a true transitional quarter, where the Company made the switch from distributing popular vaporizer brands and liquids, to building, expanding, and focusing on the HONEYSTICK brand and further expanding its presence in the cannabis space. I believe this transition was in the long term best interest of VPR Brands LP and look forward to the further emergence and expansion of the HONEYSTICK brand as well as our portfolio of cannabis business," said Dan Hoff, COO of VPR Brands, LP.

Although our sales are not segregated by brand or product category, our primary revenue source is from vaporization devices specifically created for use with medical cannabis and recreational marijuana. These devices are specifically created for use with extract oils and concentrates which are vaped, providing optimal results and the best experience for patients and recreational users. Vaporizers are far more convenient and discrete compared to traditional cannabis use methods. These units are compact, easy to carry and concealable. Modern cannabis vaporizers do not emit distinct and lingering odors that are affiliated with traditional marijuana use. We believe that portable vaporizers are the fastest growing delivery mechanism for marijuana. Our team is currently working with other market leaders within cannabis growth and extraction to innovate and further educate the marketplace on its advantages.

About VPR Brands LP:

VPR Brands is a technology company whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The Company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the Company on the web at www.vprbrands.com.

Forward-Looking Statements:  
This news release contains statements that involve expectations, plans or intentions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

CONTACT: Contact Information: VPR Brands, LP Kevin Frija CEO (954) 715-7001 info@vprbrands.com
Categories: State

Pacific Mercantile Bank Provides Financing to CASE Systems, Inc.

23 May 2017 - 7:00am

COSTA MESA, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Pacific Mercantile Bank (“the Bank”), the wholly owned subsidiary of Pacific Mercantile Bancorp (NASDAQ:PMBC), today announced that it has extended a term loan and commercial line of credit to CASE Systems, Inc. (“CASE”) to support the company’s growth.  In addition to the financing, CASE Systems utilizes a full suite of Pacific Mercantile Bank’s depository products and cash management services. 

Based in Irvine, CASE Systems, Inc. is a leading provider of public safety communication systems that provide reliable voice and text communication wherever there is a need for security solutions.  CASE opened its doors in 2008, with a goal to continue manufacturing and supporting the original proven solar powered, wireless emergency call boxes familiar along the highways of California and New York.  CASE’s public safety communications systems are utilized on freeways, bridges, tunnels, parking lots, campuses, and industrial complexes, as well as along remote roadways, parks and recreational areas.

“We are seeing many new applications for our products in the public safety market, and it was important for us to find a banking partner that had the financial strength and flexibility to meet our needs for bidding on larger projects,” said Sebastian Gutierrez, President and CEO of CASE Systems, Inc.  “Pacific Mercantile Bank provided the financing we need to pursue our growth opportunities, while showing us a level of personal attention that we hadn’t experienced in our prior banking relationships.”

“CASE has created a strong position in the public safety market by providing the most reliable products and maintenance service available,” said Tom Vertin, President and Chief Executive Officer of Pacific Mercantile Bank.  “We are very pleased to support their innovative work to broaden the use of solar powered emergency call boxes to improve public safety across the country.”

About Pacific Mercantile Bank

Pacific Mercantile Bank opened for business March 1, 1999. The Bank, which is FDIC insured and a member of the Federal Reserve System, provides a wide range of commercial banking services to businesses, business owners and business professionals through its combination of traditional banking offices and comprehensive, sophisticated electronic banking services.

The Bank, headquartered in Orange County, operates a total of nine offices in Southern California, located in Orange, Los Angeles, San Diego, and San Bernardino counties. In addition, the Bank offers comprehensive online banking services accessible at www.pmbank.com.  Pacific Mercantile Bancorp (NASDAQ:PMBC) is the parent holding company of Pacific Mercantile Bank.

Forward-Looking Information

This news release contains statements regarding our expectations, beliefs and views about our plans to continue to build our loan portfolio and supporting systems and processes.  These statements, which constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, can be identified by the fact that they do not relate strictly to historical or current facts. Often, they include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." These forward-looking statements are subject to numerous risks and uncertainties. Actual results may differ materially from the results discussed in these forward-looking statements because such statements are inherently subject to significant assumptions, risks and uncertainties, many of which are difficult to predict and are generally beyond our control. These risks and uncertainties include, but are not limited to, the following: the impact of interest rates and other external economic factors and competition among financial services providers. We undertake no obligation (and expressly disclaim any such obligation) to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. For additional information concerning factors that could cause actual conditions, events or results to materially differ from those described in the forward-looking statements, please refer to the factors set forth under the headings "Risk Factors" in our most recent Form 10-K and 10-Q reports and to our most recent Form 8-K reports, which are available online at www.sec.gov. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition.

CONTACT: Pacific Mercantile Bank Contact: Robert Anderson EVP & Chief Banking Officer 714-438-2500
Categories: State

LKQ Corporation to Present at Upcoming Investor Conference

19 May 2017 - 9:00am

CHICAGO, May 19, 2017 (GLOBE NEWSWIRE) -- LKQ Corporation (Nasdaq:LKQ) today announced that members of its senior management will be presenting at the following investor conference:

Jefferies 2017 Global Automotive Aftermarket Investor Conference May 24, 2017InterContinental New York Barclay, New York  

Materials used during the presentations will be posted to the Company's website: www.lkqcorp.com on the day of the conferences.

About LKQ Corporation

LKQ Corporation (www.lkqcorp.com) is a leading provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles. LKQ has operations in North America, Europe and Taiwan. LKQ offers its customers a broad range of replacement systems, components, equipment and parts to repair and accessorize automobiles, trucks, and recreational and performance vehicles.

CONTACT: Joseph P. Boutross LKQ Corporation Director, Investor Relations (312) 621-2793 jpboutross@lkqcorp.com
Categories: State

Sensata Technologies Announces Appointment of Connie Skidmore to Board of Directors

19 May 2017 - 7:02am

HENGELO, the Netherlands, May 19, 2017 (GLOBE NEWSWIRE) -- Sensata Technologies (NYSE:ST) today announced that its Board of Directors has appointed Connie Skidmore as a new director of the Company. Ms. Skidmore is filling the vacancy on the Board created by the departure of Michael J. Jacobson whose Board service ended at the Annual General Meeting in May 2017. Skidmore brings more than 30 years of audit, financial and leadership experience to the Board and the Audit Committee.

“Today’s appointment reflects our comprehensive approach to Board succession planning which is rooted in Sensata’s commitment to value creation,” said Paul Edgerley, Chairman of the Board of Directors at Sensata Technologies. “As Sensata continues to invest for future growth, while sustaining margin expansion, I am confident that we will benefit from Connie’s financial acumen and experience working with technology and manufacturing companies. Finally, I also want to thank Michael Jacobson for his dedicated service to Sensata since our initial public offering in March 2010.”

During her more than 30-year tenure with PricewaterhouseCoopers (PwC), Ms. Skidmore worked with a variety of public and privately held companies advising on accounting and tax strategies, global corporate structuring, due diligence projects, employee benefit plans, corporate mergers and acquisitions, stock options, and syndications.  She served as the primary tax advisor on numerous initial public offerings and other SEC filings.  During her years as an advisor, she developed deep expertise in the technology, manufacturing, and extractive industries.  Prior to joining PwC, Ms. Skidmore was a tax specialist with the Internal Revenue Service.  She holds a B.S. degree from Florida State University and a M.S. degree in Taxation from Golden Gate University.  Recently, she completed the Directors College program at Stanford Law School.

“I am honored to have the opportunity to serve on Sensata’s Board of Directors and Audit Committee. I look forward to working with the Board to best serve the interests of Sensata’s shareholders,” said Ms. Skidmore.

Ms. Skidmore currently serves as a Director for Comfort Systems USA, Inc. and ShoreTel, Inc.

About Sensata Technologies:

Sensata Technologies is one of the world’s leading suppliers of sensing, electrical protection, control and power management solutions with operations and business centers in thirteen countries.  Sensata’s products improve safety, efficiency and comfort for millions of people every day in automotive, appliance, aircraft, industrial, military, heavy vehicle, heating, air-conditioning, data, telecommunications, recreational vehicle and marine applications.  For more information, please visit Sensata’s web site at www.sensata.com.

CONTACT: Contact: Investors: Joshua Young (508) 236-2196 joshua.young@sensata.com Media: Alexia Taxiarchos (508) 236-1761 ataxiarchos@sensata.com
Categories: State

MariMed Update: Q1 Revenue Doubles, Cannabis Services and Products Business Growing

18 May 2017 - 7:28am

BOSTON, May 18, 2017 (GLOBE NEWSWIRE) -- MariMed Inc. (OTCQB:MRMD) has over the past few years quietly developed its client base and revenue in the legal cannabis industry. Management anticipates MariMed will be on an even faster growth trajectory as many of its projects will be coming to fruition.  MariMed reported strong revenue growth for 2016, which has continued into 2017.  MariMed Inc. revenue for the three months ended March 31, 2017 was $1,150,719, nearly double the revenue of $614,456 for the comparable quarter 2016.  MariMed more than doubled revenue in 2016 over 2015, increasing from $1.27 million in 2015 to $3.56 million in 2016. Substantially all the revenue was attributable to its subsidiary MariMed Advisors and its cannabis services and products business.

Over the past few years, MariMed has written and supplied expertise for winning applications for medical cannabis facility licenses in five states.  The Company has developed and funded five cannabis facilities, and provides ongoing management oversight for clients in Delaware, Illinois, and Nevada. MariMed is now developing six cannabis facilities for clients in Massachusetts and Maryland. Concurrently, MariMed has created Kalm Fusion™, a brand of precision dosed cannabis infused products.  After years of development and consumer testing in Delaware and Rhode Island, MariMed has introduced these products into more than 40 dispensaries in Illinois. MariMed is in the process of securing licensed partners to distribute Kalm Fusion into hundreds of licensed dispensaries in additional states.

“The MariMed team has been working extremely hard over the past several years to build an impressive legal cannabis services and licensed product business,” stated Mr. Robert Fireman, CEO of MariMed Advisors, a wholly owned subsidiary of MariMed Inc.  “We now have a broad range of clients that cross the entire cannabis business continuum, from aspiring license applicants to established businesses that are selling our Kalm Fusion line of products and expanding their facilities to meet demand.  Management is extremely pleased with the progress and encouraged by our current growth trajectory.  We are confident that we are ideally positioned to capitalize on the massive potential of the legal cannabis industry in North America.”

Legal cannabis is currently a $7 billion-dollar industry in the U.S., and The Cowen Report projects it will grow to $50 billion in the U.S. by 2026.  Cannabis has been legalized for medical or recreational use in 28 states and Washington DC, and legalization is being considered in additional states.  Medical cannabis is legal throughout Canada and legislation legalizing recreational use nationwide is expected to pass in 2017.

“MariMed is establishing a growing North American footprint and recognition for best practices in facility operations and innovative precision dosed cannabis products in numerous states,” said Mr. Jon Levine, CFO of MariMed Advisors.  “Even more opportunities are opening up as aspiring licensees seek our assistance in locations considering legalizing cannabis.  As a public company singly focused on the cannabis industry, we believe that with access to the capital markets, we will be better able to develop our product development and distribution network, and provide our clients with the funding needed to secure licenses, design, build and operate their facilities more expeditiously.”

About MariMed (formerly Worlds Online):
MariMed Inc. is an industry leader in the design, development, operation, funding and optimization of medical cannabis cultivation and production centers and dispensaries. The MariMed team has developed, state of the art and regulatory compliant facilities in multiple states. These facilities are replicable and scalable model of excellence in horticultural principals, cannabis production, product development and dispensary operations. We are on the forefront of medical research working to create precision dosed products to treat specific conditions. For further information visit MarimedAdvisors.com

Forward Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc., that is based on the beliefs of MariMed Inc. management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the economic environment and changes in technology. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites of any other party referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

CONTACT: CONTACTS: MariMed Business Development Jon Levine, CFO, MariMed Advisors 844-244-0200 jlevine@marimedadvisors.com Investor Relations +1-866-976-4784 ir@marimedadvisors.com Media Relations Julie Shepherd, Accentuate PR 847-275-3643 Julie@accentuatePR.com
Categories: State

North Country HealthCare Selects Mushroom Networks for High-Performance, Reliable Mobile Internet Connectivity

18 May 2017 - 7:00am

SAN DIEGO, May 18, 2017 (GLOBE NEWSWIRE) -- Mushroom Networks, an innovator in Broadband-Bonding and Software-Defined Wide Area Networking (SD-WAN) platforms, today announced that North Country HealthCare has selected Mushroom Networks’ Truffle and Portabella platforms to deliver mobile Internet connectivity to its mobile medical clinic, nicknamed the “Big Orange Bus.” By supplying this mobile medical platform with reliable, high-performance Internet, North Country HealthCare is able to serve its rural constituency by bringing critical healthcare and dental services directly to their often difficult-to-reach areas.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3b4d0f9f-937a-4948-9a0f-c7e3f435fdb2

“Prior to working with Mushroom Networks, we were very limited in the connectivity services we could deliver to our mobile medical unit,” said Joe Connell, North Country’s IT manager. “In fact, they often had to drive around their remote location just to find that extra ‘bar’ for even basic email connectivity. With Mushroom Networks’ Truffle and Portabella platforms, our mobile physicians and nurses have access to all of the information sources they need to serve the patient in front of them in these rural locations.”

North Country HealthCare is a community healthcare center that provides general medical and dental services primarily to under-served communities in 14 locations across northern Arizona. Their mobile medical unit is essentially a medical office on wheels in the form of a modified recreational vehicle (RV). This innovative platform has a regular route providing immunizations, treatment for sudden illness, general physicals, and more to schools and other communities throughout the Flagstaff area. In addition to our services in the schools, the mobile medical unit makes weekly visits to a shelter in Flagstaff to provide basic medical care to the local homeless population.

Prior to using Mushroom Networks SD-WAN technology, North Country relied on a single SIM card to connect the mobile medical unit to its data center. This meant spotty connections and an inability to access the network for electronic records and other applications. After struggling with various solutions, North Country came to Mushroom Networks, which placed its Portabella platform on the mobile medical unit and connected the system directly to the Truffle platform back at headquarters. This enabled staff to easily access their VoIP mailboxes, network file shares, scanning documentation, and electronic medical records as if they were back at the office.

The Portabella is a 3G / 4G / LTE bonding device with Broadband Bonding technology that provides cost-effective portable Internet access for mobile and portable deployments. Portabella provides uplink and downlink bonding for any protocol via bonding together multiple cellular wireless Internet access cards for increased performance and reliability. Depending on the model, Portabella aggregates the capacity of as many as two, four, or eight cellular data modems (external or embedded depending on the model) providing increased access bandwidth in both uplink and downlink directions and application optimization for a variety of real-time and non-real-time applications.

Cahit Akin, CEO of Mushroom Networks, said, “Portabella’s ability to adjust its bonding algorithms adaptively was tailor made for applications like their advance mobile medical unit. We look forward to continue working with North Country HealthCare as mobility continues to evolve with technologies like 5G and others.”

To learn more about Mushroom Networks’ solutions, visit https://www.mushroomnetworks.com

About Mushroom Networks
Mushroom Networks, Inc., is a privately held company based in San Diego, CA, providing patent pending Broadband Bonding solutions to a range of Internet connection applications. The company’s flagship product line serves SMBs, enterprises, multi-tenant buildings, and broadband service providers and bonds dissimilar broadband access technologies forming a single highly reliable broadband pipe that can easily scale based on needs. Mushroom Networks was the winner of the 2015 Most Innovative Product award by CONNECT, finalist for the coveted 2012 San Diego Business Journal Innovation Award, winner of the XCHANGE Tech Innovators Xcellence Award, and winner of the 2008 CONNECT® ‘Most Innovative New Product’ award, Network World’s "top technology trend of 2008" award. For more information, please visit https://www.mushroomnetworks.com or call (858) 366-9255.

CONTACT: Media Contact: Jay Nichols Mushroom Networks, Inc. jnichols@mushroomnetworks.com Tel: (858) 366-9255 ext 6039
Categories: State

Plan 1 at Delano at Eastwood Village Enchants With Beautifully Planned Interiors, Distinctive Modern Features

17 May 2017 - 6:10pm

IRVINE, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- Brookfield Residential’s Delano at Eastwood Village in Irvine elevates the beauty of attached new-home living with three luxury townhome designs that include the stunning Plan 1. This exquisitely detailed, two-story floorplan makes an impression at first glance, beginning with the charming entry courtyard that creates a welcoming ambience. The design’s spacious interior spans 1,533 square feet with three bedrooms, including a lavish master suite set apart from the secondary bedrooms, two baths, an optional den, and a two-car garage with direct access plus storage. The open interior showcases comfortable dining and living areas leading to a covered deck, while the gourmet kitchen is highlighted by granite countertops, Whirlpool® stainless steel appliances, and a center island. As with all of Delano’s floorplans, Plan 1 features the Connected Home package, which offers the latest home automation products. This amenity allows residents to control the front door lock, Lutron® light switches, a programmable Wi-Fi thermostat and more, right from their smartphones or tablets. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7b9e8eb9-6755-4d9e-9163-be163e70d676

Heightening the appeal is the unparalleled setting in Irvine’s Eastwood Village, where homeowners enjoy a host of lifestyle perks that range from premier recreational amenities to inclusion in top-rated Irvine schools.

Potential homebuyers interested in any of Delano’s three elegant attached designs are encouraged to tour the models today or go to www.BrookfieldSoCal.com now for details.

“Delano’s designs are truly extraordinary with smartly planned interiors and modern amenities that are beautifully reflected in our Plan 1,” said Mercedes Meserve, Vice President of Marketing for Brookfield Residential Southern California.  

Delano continues Brookfield Residential’s legacy of creating the best places to call home with three townhome designs spanning from approximately 1,533 to 1,918 with prices from the high $600,000s.

Set in Eastwood Village, residents enjoy amenities, such as inviting parks with Jr. Olympic-size pools, wading pools and spas; sports fields and courts; tot lots; shade structures; picnic and barbecue areas; and more. The surrounding area offers great shopping, restaurants and entertainment all conveniently close to home.

School-aged residents attend top-rated educational institutions, including Santiago Hills Elementary, Sierra Vista Middle School and Northwood High School.

Eastwood Village, one of the Villages of Irvine created by the Irvine Company, provides residents with the opportunity to live close to nature with spacious parks and endless scenic trails, all leading to the village center.  The thoughtfully designed plan creates a friendly village atmosphere where families can walk to the brand new Eastwood Elementary School (opening fall 2017), meet on the soccer fields or tennis courts and picnic under eucalyptus trees.  Life revolves around family here, where neighborhoods are exquisitely framed and connected by a walking paseo, large anchor parks and a new, convenient underpass to the Jeffrey Open Space Trail.

Irvine Company Community Development, the nation’s premier master planner, created the Villages of Irvine®, which was ranked by a John Burns Real Estate Consulting report as the top-selling master-planned community in the U.S. in 2016. The Villages of Irvine delivers timeless architecture set among the best park system in Southern California, the best public schools in the state, and the safest city in America — for 12 straight years, according to FBI statistics. This highly acclaimed community is also renowned for its more than 57,000 acres of preserved open space; world-class shopping, dining and entertainment; and modern business centers — all of which work together to create an unparalleled quality of life. Thanks in large part to the Villages of Irvine, Money magazine routinely ranks the city of Irvine as the one of the state’s “Best Places to Live.” For more information, please visit VillagesofIrvine.com. 

To visit Delano at Eastwood Village from the 405 or 5 freeways, exit Jeffrey Road and head east. Turn left on Encore to enter the village. The sales gallery is open daily from 10 am to 6 pm, except on Wednesdays from 2 pm to 6 pm. The address is 58.5 Parkwood. For more information, call (888) 750-8868.

Prices effective date of publication.

About Brookfield Residential (Southern California)

Brookfield Residential Southern California (Los Angeles and San Diego) a division of Brookfield Residential, is committed to being more than a homebuilder. We strive to create the best places to call home. The Brookfield Residential Southern California (Los Angeles and San Diego) team has the passion, the expertise and the local knowledge to craft homes and neighborhoods that speak to homebuyers at every stage of life. We are an award-winning homebuilder and industry leader with an exceptional reputation for quality, design, and customer service. Please visit www.BrookfieldSoCal.com for more information.

Brookfield Residential Properties Inc. is a leading land developer and homebuilder in North America. We entitle and develop land to create master-planned communities, sell lots to third-party builders, and operate our own home building division. We also participate in select, strategic real estate opportunities, including infill projects, mixed-use developments, and joint ventures. Further information is available at BrookfieldResidential.com.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

CONTACT: CONTACT:                                         Brittany Duhs – BrittanyD@HayesMartin.com (949) 417-1799
Categories: State

Experience Summer Adventure at Vermont Ski Resorts

16 May 2017 - 2:34pm

Montpelier, VT, May 16, 2017 (GLOBE NEWSWIRE) -- Summer is almost here and that means longer days, warmer nights and making memories with friends and family in the beautiful mountains of Vermont. Visitors and friends have come to know and love all that Vermont ski and snowboard resorts offer in the winter and when the season’s change those offerings don’t stop, they simply transition to summer activities. Vacationers coming to Vermont can expect days full of outdoor and indoor adventure, relaxing afternoons at the spa and golf course, and evenings filled with the melodic sounds of outdoor concerts. Of course, no day in Vermont is complete without a fulfilling and delectable meal of fresh farm to table offerings, and Vermont’s expansive network of local breweries and distilleries ensure that there is something to please event the pickiest of palettes.

Hike, Bike and Zip Through Vermont
There is no shortage of outdoor activities in the Green Mountains. Vacationers can let their inner adventurer out on Stowe Mountain Resorts’ Tree Top Adventure Course or Bromley Mountain’s Sun Mount Flyer, a ZipRider®, that zooms at speeds up to 50mph with a 700-foot vertical drop.

For those who prefer to stay on the ground there are plenty of activities to choose from like hiking and mountain biking. The birthplace of the Long Trail and the Appalachian Trail is at the tallest peak in southern Vermont – Stratton Mountain. Hikers there can choose from a variety of trail options and even partake in a free Lole Meet-Up. Connect to the Long Trail from Bolton Valley’s 1100 acres of outdoor recreational trails, or explore Mad River Glen’s new network of trails on General Stark Mountain.

Vermont’s mountain biking scene has boomed in the last few years and resorts like Burke Mountain offer close to one hundred miles of cross country trails for bikers, new and seasoned, to pedal through to their heart’s content. For bikers looking to reach higher elevations, many Vermont ski resorts like Killington Resort, Sugarbush Resort, Mount Snow Resort and Okemo Mountain Resort offer lift served mountain biking where the chairlifts are outfitted with special bike racks to assist riders as they make their effortless ascent to the summit. Bikers can then rip down the mountainside knowing that just a short chairlift ride separates them from another exhilarating descent.

Calling all Families
Families can leave their troubles behind when they visit the Green Mountain State. Many resorts offer summer camps and at Jay Peak Resort the Raised Jay camps will get children outdoors, making friends, learning new skills and most importantly, having fun. At Sugarbush Resort summer camp comes with weekly themes like farm-to-plate cooking, water sports, climbing and more.

Looking for activities that the whole family will enjoy? Stop by America’s Family Resort, Smugglers’ Notch, to play around in their new Fun Zone 2.0 with an arcade, climbing wall, laser tag and much more. The activities continue outdoors at Okemo Mountain Resort where families can take a fun and relaxing chairlift ride on the scenic Sunburst Six, followed by a hike back down or a return ride.

Find Balance in Vermont
While summer should be full of adventure, it should also be a time where visitors get to relax and rejuvenate. This is why Vermont resorts offer top of the line spa treatments, fitness centers and leisure activities like golf and yoga.

Choose from spas like the Killington Grand Spa at Killington Resort or the NatureSpa at Mount Snow where a full menu of massages, facials and botanical skin treatments are offered. Before indulging in a maple body scrub or full body massage, visitors can find balance in a peaceful yoga or meditation class, step outside on a guided nature walk or break a sweat at one of the many resort fitness and training centers. Trapp Family Lodge offers a weekly Summer Trails Series where visitors can partake in a group 5k and then choose to unwind on their own or head on over to the spa.

Golfers can perfect their swings at one of many  Vermont’s resort golf courses like The Woodstock Country Club which has been named one of the top 100 golf resorts by Golf Magazine.

2017 Ski Vermont Summer Press Kit

Ski Vermont (Vermont Ski Areas Association) is a proud ambassador of the thriving winter tourism industry in Vermont, where the legislature has designated skiing and snowboarding as the official state sports. Vermont is not only the #1 ski state in the East and among the top ski states in the US, but also reigns supreme in snowmaking quality and coverage, variety of terrain and historical impact on the sports of skiing and snowboarding - making it one of the most significant ski and ride destinations in the world. Ski Vermont’s mission is to help create a legislative, economic and social environment in which the state's ski areas can grow and prosper. It serves over 20 Alpine and 30 Nordic member resorts in three major areas: Governmental Affairs, Marketing and Public Affairs.

###

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2ebeba45-e82b-43e8-a351-a233d12404ee

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/190bbb35-ee26-4af2-ad08-045577197d79

CONTACT: Choe Elliott Ski Vermont 8022232439 chloe@skivermont.com
Categories: State

SeeThruEquity Initiates Coverage on AXIM® Biotechnologies (OTC: AXIM) With a Target Price of $17.0

16 May 2017 - 9:00am

NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies has initiated coverage of AXIM with a price target of $17.0.

The full research report is available here. Highlights from the report include:

Large market opportunity
The market for cannabis-based pharmaceutical and nutraceuticals is emerging and quickly growing. Indeed, legal cannabis is among the fastest growing industries in the United States, estimated at $7.1 billion in 2016, including both medical and recreational uses, according to a report by New Frontier and ArcView Market Research. Longer term, the market has been forecast by Cowen to be as much as $50 billion within ten years assuming federal legalization takes place in the United States. We note that progress towards legalization is likely to have an impact on the valuation and perception of Axim and all cannabis companies, however the company’s strategy includes a global perspective, legal nutraceuticals, and clinical products – not recreational cannabis.

CanChew+ Nutraceutical Sales, Phase 2 results on MedChewRx, are areas to watch in 2017
We see several key events ahead for Axim as it advances its cannabis-based clinical pipeline and accelerates commercial activities for its nutraceutical and cosmetic products, led by CanChew+. The company’s initial nutraceutical products, and its lead clinical candidates, feature its patented delivery systems, a chewing gum formulation that management believes is an ideal oral, transmucosal controlled-release delivery system. Axim has launched CanChew®, a patented, controlled-release cannabidiol extracted from industrial hemp chewing gum for general well-being, which is currently available in all 50 US States and over 40 countries internationally. The company has issued an outlook for high growth in this area, with more than ten commercial-ready products in the nutraceutical, cosmetic, and oral care markets. Axim also has more than 20 clinical products planned, and is in the process of developing pharmaceutical-candidates using chewing gum and other delivery methods, such as suppositories, transdermal delivery systems, and transconjunctival, among others, for a number of indications treating pain, spasticity, anxiety, nausea and vomiting, cachexia, and other under the MedChewRx™ brand family. The company expects to report trial results during 2017, which may provide insight into this strategy and the delivery mechanism’s possible applicability to other indications.

Initiate coverage with a price target of $17.00
We initiate coverage of Axim with a price target of $17.00. We see Axim as an intriguing speculative company targeting the rapidly growing market for legal cannabis products with what appears to be differentiated intellectual property and bold development plans. The company has several key events ahead as it attempts to grow its nutraceutical and cosmetic product lines and advances its clinical pipeline led by MedChew. Management has also stated its intention to uplist to a national exchange, which would be a significant corporate milestone, if accomplished.

SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The full report will also be available on the AXIM website under Investor Relations.

About AXIM®
AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com

About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City. For more information visit www.seethruequity.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

CONTACT: Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com Investor Relations Contact: Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 284-9474 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416 Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Categories: State

Uniroyal Global Expands its Global Presence

16 May 2017 - 8:30am

SARASOTA, Fla., May 16, 2017 (GLOBE NEWSWIRE) -- Uniroyal Global Engineered Products, Inc. (OTCQB:UNIR), a leading global provider of vinyl-coated fabrics and soft trim technologies serving the automotive, recreational, industrial, contract, hospitality and healthcare markets, reports that it is currently implementing expansion plans and continued investment in the Asian market, beginning with a new sales, engineering and marketing office in Shanghai’s Financial District in Pudong.  The office will provide sales, marketing technical and logistical support, as well as offer a hub of innovation for the research and development of new vinyl colors, patterns, and designs targeted towards the Asia-Pacific automotive market.

“China is a significant piece of Uniroyal Global’s growth strategy and this expansion reflects our commitment to investing in one of the largest and most dynamic markets in the world.  Capitalizing on the successful integration of our acquisitions, Uniroyal is continuing to look forward to expanding our global footprint. Pudong is a natural fit for our office, as it is close to all of our major customers in the region. We expect the office to serve as an innovation center to enhance product offerings to the Asian market,” said Uniroyal CEO Howard R. Curd.

“With the Asia-Pacific market accounting for 50% of the global coated fabrics market, our presence in Shanghai positions us to showcase our world class design capabilities and expand our business in this growing market.  In addition to our strong presence in the U.S. and Europe, the China office will enable us to broaden our global reach and pursue additional opportunities in the automotive and mass transportation markets,” added Mike Raines, EVP and Global Commercial Director. 

About Uniroyal Global Engineered Products, Inc.:

Uniroyal Global Engineered Products, Inc. (Symbol:UNIR) is a leading global provider of vinyl-coated fabrics and soft trim technologies. Our companies in the U.S. and Europe utilize 500,000 square feet of manufacturing capacity and feature more than 400 employees dedicated to delivering outstanding products engineered for exceptional performance.  Uniroyal Global’s coated fabrics and soft trim components are featured in many consumer and industrial applications including automotive seating and interior components, commercial and hospitality seating, medical equipment, healthcare facilities and athletic equipment primarily in North America and Europe.  Among Uniroyal Global’s collection of innovative products are the renowned and industry-preferred brands, Naugahyde® and Ambla®.  For more information on Uniroyal Global Engineered Products, Inc., please visit uniroyalglobal.com

Forward-Looking Statements:

Except for statements of historical fact, certain information contained in this press release constitutes forward-looking statements, including, without limitation, statements containing the words “believe,” “expect,” “anticipate,” “intend, “should,” “planned,” “estimated” and “potential” and words of similar import, as well as all references to the future. These forward-looking statements are based on Uniroyal Global Engineered Products, Inc.’s current expectations. The Company cautions investors that any forward-looking statements made by the Company are not guarantees of future performance and that a variety of factors could cause the Company´s actual results and experience to differ materially from the anticipated results or other expectations expressed in the Company´s forward-looking statements. The risks and uncertainties which may affect the operations, performance, development and results of the Company´s business include, but are not limited to, the following: uncertainties relating to economic conditions, uncertainties relating to customer plans and commitments, the pricing and availability of equipment, materials and inventories, currency fluctuations, technological developments, performance issues with suppliers, economic growth, delays in testing of new products, the Company’s ability to successfully integrate acquired operations, the Company’s dependence on key personnel, the Company’s ability to protect its intellectual property rights, the effectiveness of cost-reduction plans, rapid technology changes and the highly competitive environment in which the Company operates. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

CONTACT: Contacts Uniroyal Global Engineered Products, Inc. Corporate Contact: Elizabeth Henson, 941-870-3950 LHenson@uniroyalglobal.com Or Uniroyal Global Engineered Products, Inc. Public Relations: TTC Group, Inc. Vic Allgeier, 646-290-6400 vic@ttcominc.com
Categories: State

SeeThruEquity Initiates Coverage on AXIM® Biotech (OTC: AXIM) With a Target Price of $17.0

16 May 2017 - 8:00am

NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies has initiated coverage of AXIM with a price target of $17.0.

Highlights from the report include:

Large market opportunity
The market for cannabis-based pharmaceutical and nutraceuticals is emerging and quickly growing. Indeed, legal cannabis is among the fastest growing industries in the United States, estimated at $7.1 billion in 2016, including both medical and recreational uses, according to a report by New Frontier and ArcView Market Research. Longer term, the market has been forecast by Cowen to be as much as $50 billion within ten years, assuming federal legalization takes place in the United States. We note that progress towards legalization is likely to have an impact on the valuation and perception of Axim and all cannabis companies, however the company’s strategy includes a global perspective, legal nutraceuticals, and clinical products – not recreational cannabis.

CanChew+ Nutraceutical Sales, Phase 2 results on MedChewRx, are areas to watch in 2017
We see several key events ahead for Axim as it advances its cannabis-based clinical pipeline and accelerates commercial activities for its nutraceutical and cosmetic products, led by CanChew+. The company’s initial nutraceutical products, and its lead clinical candidates, feature its patented delivery systems, a chewing gum formulation that management believes is an ideal oral, transmucosal controlled-release delivery system. Axim has launched CanChew®, a patented, controlled-release cannabidiol extracted from industrial hemp chewing gum for general well-being, which is currently available in all 50 US States and over 40 countries internationally. The company has issued an outlook for high growth in this area, with more than ten commercial-ready products in the nutraceutical, cosmetic, and oral care markets. Axim also has more than 20 clinical products planned, and is in the process of developing pharmaceutical-candidates using chewing gum and other delivery methods, such as suppositories, transdermal delivery systems, and transconjunctival, among others, for a number of indications treating pain, spasticity, anxiety, nausea and vomiting, cachexia, and other, under the MedChewRx™ brand family. The company expects to report trial results during 2017, which may provide insight into this strategy and the delivery mechanism’s possible applicability to other indications.

Initiate coverage with a price target of $17.00
We initiate coverage of Axim with a price target of $17.00. We see Axim as an intriguing speculative company targeting the rapidly growing market for legal cannabis products with what appears to be differentiated intellectual property and bold development plans. The company has several key events ahead as it attempts to grow its nutraceutical and cosmetic product lines and advances its clinical pipeline led by MedChew. Management has also stated its intention to uplist to a national exchange, which would be a significant corporate milestone, if accomplished.

SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The full report is also available on the AXIM website (click here).

About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.

About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City. For more information visit www.seethruequity.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

CONTACT: Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com Investor Relations Contact: Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 284-9474 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416 Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Categories: State

IEC Launches Crop Management Services Including Vineyard Grapes and Medical Marijuana

15 May 2017 - 8:20am

TEMECULA, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- International Endeavors Corporation (OTCBB:IDVV) today announced it has launched its crop management services in the San Diego and Temecula regions of Southern California.

While building our crop management services department catering to local grape growers we realized there was a void in the medical marijuana residential based licensed grows.

There is a myth that growing marijuana is very easy, that you can just plant it and it grows without any maintenance. This could not be any further from the truth if you are looking for a high quality plant such as what you would purchase in a dispensary. To grow marijuana properly you must maintain a proper soil, chemical balance (if any), lighting, temperature and more. This of course can be done and is done by most growers, but there is a portion of potential growers such as cancer patients that cannot do it on their own and instead are left paying a high retail price at a local dispensary.

IEC is proud to launch a crop management service to cater to the needs of those that are truly medically challenged that can’t grow on their own. Starting with a consultation for a clients needs we can assist clients on setting up their home based grow operation to be in compliance with current California laws and allow them to save money. We anticipate customers can save as much as 50% by joining our service vs. buying from the dispensary. The customer can also rest assured that they are getting what they are paying for because it is grown in or on their property.

IEC is launching its medical marijuana crop management services starting in Temecula and San Diego areas of Southern California with plans to grow to other areas as legalization progresses. Services IEC plans to provide include the following:

  • Seed and plant selection
  • Soil management
  • Climate control
  • Chemical balancing
  • Lighting installation and maintenance
  • Trimming
  • Harvesting
  • Drying
  • Cloning
  • Distribution of unused harvest (if permitted by law)

IEC plans to expand its crop management services to other areas as increased demand and legalization takes place.

About International Endeavors Corporation

International Endeavors Corp (IEC) was created in 2014 by Nate Engel, an avid outdoorsman with a goal of developing properties throughout North America providing themed overnight adventures catering to recreational vehicle owners and others interested in the popular experience of ”Glamping.”

IEC’s properties will include Safari Tents, Yurts, Retro RV Campers Tee-Pees’s and Treehouses all laid out in master planned wine vineyards featuring amenities such as restaurants and retail shops.

IEC has plans to build throughout North America starting with its first resort(s) being developed on recently purchased properties in North San Diego County, to offer overnight accommodations to the over 100 Wineries in the area between Temecula, California Wine Country and San Diego, California. The properties are on the popular Highway 79 which boasts of a rich history of “Old California.”

PRIVATE BRANDED WINES

IEC has also has developed and is developing several privately branded wines such as RVINO that in most cases will be produced on site.

WEBSITE

The company has launched a website to update shareholders at www.internationalendeavorscorp.com

Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. The Company would like to assure all investors that in all cannabis related actions the Company is conferring with counsel to be sure any business activities are deemed legal.

CONTACT: Contact nate@internationalendeavorscorp.com 951-296-1024
Categories: State

Acology Continues Strong Pace, Highlights of 10Q in Letter to Shareholders

15 May 2017 - 7:30am

CORONA, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- A Letter from CEO Curt Fairbrother

Dear Shareholders:

With Friday’s release of our 10Q our company’s health and strength continues to be decisively displayed along with the determination and commitment that have made the last 8 months the strongest of our existence. (OTC:ACOL)

The facts are simple; we’ve seriously reduced our operational and advertising costs while continuing to grow. Net profits have increased YOY and the explosive growth in our first quarter continues unabated. 2017 will set new records for profitability. Our debt continues to diminish and no new loans have been received and none are contemplated. Sales of new products now account for 25% of total revenue and are growing month to month. In short, the state of Acology’s health is thriving.

In answer to the many inquiries that we receive from our stockholders about our plans for enhancing our national and international marketing profile, we are now confident that we can increase spending and continue to improve our global position. In addition, our revenue pace continues to out-perform our expectations, our production capacity continues to easily handle our growth and our inventory levels are good.

Acquisition talks with EZ Health Solutions, including the ownership of intellectual properties, continues and our preparations to create a new CBD-Infused Health Products Division has gained momentum. There has been tremendous interest in the market about our plans to expand. Needless to say, we are very excited about our current situation and very positive about the future.

Those of you who have been with us for a while know that we’ve had remarkable success with our endeavors and have sustained us as we continued to grow and evolve. Thank you, as always, for your constant confidence and support.

Curt Fairbrother, CEO

For investor or sales information please visit Acology Inc. and D&C Distributors online or by phone. The company is located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880.

Acology trades on the OTC under the call letters ACOL. The company’s websites are www.Acologyinc.com for the hospice and palliative care industry and www.themedtainer.com for the recreational and medical marijuana industry. Orders for Acology products can be taken online and by phone. Custom orders are especially welcome.  Please send all inquiries to info@acologyinc.com or call (844) ACOLOGY (844-226-5649).  Acology can also be accessed through Twitter and Instagram at @Acologyinc

This press release includes statements that are covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events they are subject to risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the company’s current expectations. Forward-looking statements are identified by such words as “anticipates”, “projects”, “expects”, “planned”, “intends” and “believes” “estimate” “targets” and other similar expressions that indicate trends and future events. It is understood that investment entails risk on the part of the investor and could result in the loss of some or all his or her investment.

Categories: State

Collegium Reports First Quarter Financial Results and Provides Corporate Update

10 May 2017 - 3:01pm
  • Xtampza® ER prescribed by more than 3,000 physicians since commercial launch
  • Xtampza ER Notice of Allowance granted and, once issued, will extend patent protection until 2030
  • Well capitalized with $129.6 million in cash and cash equivalents
  • Conference call scheduled for today at 4:30 p.m. ET

CANTON, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the first quarter of 2017 and provided a corporate update. 

“During the first quarter, we are encouraged by the continued adoption of Xtampza ER and the positive reception by both prescribers and payors. We expect that this progress will continue to accelerate as we broaden our commercial initiatives,” said Michael Heffernan, Collegium’s CEO.

Recent Milestones Include:

Commercial

  • Through March, over 3,000 physicians prescribed Xtampza ER, including over 1,400 new prescribers in the first quarter alone. Since the launch, the average prescriber has increased prescribing each month and has written over seven prescriptions.
  • Prescriptions for Xtampza ER continue to grow. During the first quarter of 2017, Xtampza ER prescriptions increased by 106% over the fourth quarter of 2016.
  • Effective January 1, 2017, Xtampza ER is a preferred product and the exclusive oxycodone extended-release product on UnitedHealth commercial formulary with the removal of OxyContin from formulary.
  • Effective January 1, 2017, Xtampza ER is one of three preferred brands on Cigna commercial formulary. 
  • Effective April 1, 2017, Xtampza ER is the exclusive branded oxycodone extended-release product for the Medicare Part D formularies for a large national managed care organization that covers more than 3 million lives.

Intellectual Property

  • In April 2017, a Notice of Allowance for a new patent covering Xtampza ER was granted by the United States Patent and Trademark Office. The new patent, once issued, will be added to the FDA Orange Book and provide additional patent protection for Xtampza ER until December 2030.

Clinical

  • In February, Collegium announced positive topline results of a human abuse potential clinical trial, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of Xtampza ER compared to chewed Xtampza ER, and crushed immediate-release oxycodone in solution in non-dependent, recreational drug abusers. The study met its primary and secondary endpoints of lower “Drug Liking” and “Take Drug Again”.

Corporate

  • Collegium appointed Steven Passik, PhD, as Vice President of Scientific Affairs, Education and Policy.

First Quarter 2017 Financial Results 

Collegium had cash and cash equivalents of $129.6 million as of March 31, 2017 compared to $153.2 million as of December 31, 2016. Cash used in operating activities for the quarter ended March 31, 2017 (the “2017 Quarter”) was $23.7 million.

Net loss for the 2017 Quarter was $23.1 million, or $0.79 per share (basic and diluted), as compared to a net loss of $15.7 million, or $0.68 per share (basic and diluted), for the quarter ended March 31, 2016 (the “2016 Quarter”). Net loss includes stock-based compensation expense of $1.8 million and $1.1 million for the 2017 Quarter and 2016 Quarter, respectively.

Net product revenues for Xtampza ER were $2.2 million for the 2017 Quarter compared to none for the 2016 Quarter. Net product revenues increased by 67% for the 2017 Quarter compared to the quarter ended December 31, 2016. 

Research and development expenses were $2.1 million for the 2017 Quarter compared to $4.1 million for the 2016 Quarter. The decrease was primarily related to a decrease in clinical trial costs of $1.4 million due to the completion of clinical trials in 2016 and a decrease in manufacturing costs of $764,000 for Xtampza ER prior to FDA approval, partially offset by an increase in personnel related costs of $237,000.

Selling, general and administrative expenses were $22.8 million for the 2017 Quarter compared to $11.5 million for the 2016 Quarter. The increase was primarily related to: an increase in personnel related costs of $7.3 million, an increase in sales and marketing costs of $3.1 million to support the commercial launch of Xtampza ER and an increase in legal fees of $822,000.

As of March 31, 2017, there were 29,458,557 common shares outstanding.

Financial Outlook

Based on our current operating plans, we believe that our existing cash resources, together with expected cash inflows from the commercialization of Xtampza ER will fund our operating expenses, debt service and capital expenditure requirements into 2019.

Conference Call Information 

Collegium will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 4:30 p.m. Eastern Time. To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International) and refer to Conference ID: 1776-1195. An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

LIMITATIONS OF USE

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Xtampza ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Xtampza ER is not indicated as an as-needed (prn) analgesic.

The Full Prescribing Information for Xtampza ER contains the following Boxed Warning:

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 3A4 INTERACTION

Addiction, Abuse, and Misuse
Xtampza ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of these behaviors or conditions.

Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of Xtampza ER. Monitor for respiratory depression, especially during initiation of Xtampza ER or following a dose increase.

Accidental Ingestion
Accidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of oxycodone.

Neonatal Opioid Withdrawal Syndrome
Prolonged use of Xtampza ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Cytochrome P450 3A4 Interaction
The concomitant use of Xtampza ER with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving Xtampza ER and any CYP3A4 inhibitor or inducer.

IMPORTANT SAFETY INFORMATION

Xtampza ER is contraindicated in patients with: significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and hypersensitivity (e.g., anaphylaxis) to oxycodone.

Xtampza ER contains oxycodone, a Schedule II controlled substance. As an opioid, Xtampza ER exposes users to the risks of addiction, abuse, and misuse. As extended-release products, such as Xtampza ER, deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of oxycodone present.

Potential serious adverse events caused by opioids include addiction, abuse, and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, risks of concomitant use or discontinuation of cytochrome P450 3A4 inhibitors and inducers, risks due to interactions with central nervous system depressants, risk of life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients, adrenal insufficiency, severe hypotension, risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness, risks of use in patients with gastrointestinal conditions, risk of use in patients with seizure disorders, withdrawal, risks of driving and operating machinery, and laboratory monitoring. 

The most common AEs (>5%) reported by patients in the Phase 3 clinical trial during the titration phase were: nausea (16.6%), headache (13.9%), constipation (13.0%), somnolence (8.8%), pruritus (7.4%), vomiting (6.4%), and dizziness (5.7%).

For Important Safety Information including full prescribing information visit:  http://www.xtampzaer.com/

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to obtain and maintain regulatory approval of our products and product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; our plans to commercialize our product candidates and grow sales of our products; the size and growth potential of the markets for our products and product candidates, and our ability to service those markets; the success of competing products that are or become available; our ability to obtain reimbursement and third-party payor contracts for our products; the costs of commercialization activities, including marketing, sales and distribution; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our products and product candidates; changing market conditions for our products and product candidates; the outcome of any patent infringement or other litigation that may be brought against us, including litigation with Purdue Pharma, L.P.; our ability to attract collaborators with development, regulatory and commercialization expertise; the success, cost and timing of our product development activities, studies and clinical trials; our ability to obtain funding for our operations; regulatory developments in the United States and foreign countries; our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our products and product candidates; our ability to operate our business without infringing the intellectual property rights of others; the performance of our third-party suppliers and manufacturers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; the loss of key scientific or management personnel; our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2016, and those risks described from time to time in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Collegium Pharmaceutical, Inc.Unaudited Selected Consolidated Balance Sheet Information(in thousands)     March 31, December 31,  2017  2016Cash and cash equivalents$129,558 $153,225Accounts receivable 3,349  2,129Inventory 1,495  1,316Prepaid expenses and other current assets 2,064  1,905Property and equipment, net 1,007  1,038Intangible assets, net 1,973  2,103Restricted cash 97  97Other long-term assets 305  204Total assets$139,848 $162,017     Accounts payable and accrued expenses$13,281 $17,985Deferred revenue 8,695  4,944Other liabilities 3,505  4,180Stockholders’ equity 114,367  134,908Total liabilities and stockholders’ equity $139,848  $162,017       


Collegium Pharmaceutical, Inc.Unaudited Condensed Statements of Operations(in thousands, except share and per share amounts)    Three months ended March 31,   2017   2016  Product revenues, net$2,172  $  —       Costs and expenses:      Cost of product revenues 371   —    Research and development 2,130   4,062    Selling, general and administrative 22,847   11,525  Total costs and expenses 25,348   15,587       Loss from operations (23,176)  (15,587) Other income (expense), net 98   (66) Net loss($23,078) ($15,653)      Loss per share–basic and diluted($0.79) ($0.68) Weighted-average shares -basic and diluted 29,350,268   23,130,153           

 

CONTACT: Contact: Alex Dasalla adasalla@collegiumpharma.com
Categories: State

IEC To Open a Boutique Winery Featuring CBD Infused Wines

10 May 2017 - 5:00am

TEMECULA, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- International Endeavors Corporation (OTCBB:IDVV) today announced it has broken ground and has begun grating and preparing soil for its boutique winery “CBD Winery” as part of its County Line Village project located at 23446 HWY 79, Warner springs, CA 92086.

Company President Nate Engel stated “We are very excited to announce that we have broken ground on the Winery aspect of our project. We anticipate planting to begin starting in June of this year. Working with a team of experienced winemakers, we have developed what we feel is a truly revolutionary product. We have the ability to produce both red and white varieties and are currently working on a variety of CBD infused wines to bring to the market.”

Cannabidiol (CBD) is one of the most prevalent chemical compounds in the cannabis plant. Unlike the more widely known molecule, tetrahydrocannabinol (THC), CBD is completely nonpsychoactive.

Users of CBD do not expect to get “high” off of this organic chemical, however, CBD is all relaxation without intoxication.

While CBD still has an effect on your body, consuming CBD by itself isn’t going to send you on the cerebral adventure associated with THC. For decades, medical professionals and the general public overlooked CBD because psychoactive cannabis took center stage.

In more recent times however, the medical potential of CBD has taken cannabis to mainstream audiences. Preclinical trials over the past four decades have found that the cannabinoid shows promise as an:

  • Anti-inflammatory
  • Antioxidant
  • Neuroprotectant
  • Anxiolytic
  • Antidepressant
  • Anti-psychotic

CBD is often used by patients in the form of an oil. Patients with more chronic conditions such as cancer and epilepsy often use medical cannabis oil extracted from high-CBD varieties of cannabis.

When infused in a high quality wine such as the product IEC is bringing to market the experience is one of a kind.

About International Endeavors Corporation

International Endeavors Corp (IEC) was created in 2014 by Nate Engel, an avid outdoorsman with a goal of developing properties throughout North America providing themed overnight adventures catering to recreational vehicle owners and others interested in the popular experience of ”Glamping”

IEC’s properties will include Safari Tents, Yurts, Retro RV Campers Tee-Pees’s and Treehouses all laid out in master planned wine vineyards featuring amenities such as restaurants and retail shops.

IEC has plans to build throughout North America starting with its first resort(s) being developed on recently purchased properties in North San Diego County, to offer overnight accommodations to the over 100 Wineries in the area between Temecula, California Wine Country and San Diego, California. The properties are on the popular Highway 79 which boasts of a rich history of “Old California”.

PRIVATE BRANDED WINES

IEC has also has developed and is developing several privately branded wines such as RVINO that in most cases will be produced on site.

WEBSITE

The company has recently launched an updated website at internationalendeavorscorp.com. We will continue to update it to allow shareholders to view the company’s main projects.

Relevant Links

What is Glamping
https://www.glamping.com/what-is-glamping

Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. The Company would like to assure all investors that in all cannabis related actions the Company is conferring with counsel to be sure any business activities are deemed legal.

CONTACT: Contact nate@internationalendeavorscorp.com 951-296-1024
Categories: State

National General Holdings Corp. Announces Dividends on Common and Preferred Stock

9 May 2017 - 1:50pm

NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- National General Holdings Corp. (NASDAQ:NGHC) today announced that its Board of Directors approved quarterly dividends on the company's common and preferred stock as follows:

  • A cash dividend on the company's common stock of $0.04 per share.
  • A cash dividend on the company's 7.50% Non-Cumulative Preferred Stock, Series A, in the amount of $0.46875 per share.
  • A cash dividend on the company's 7.50% Non-Cumulative Preferred Stock, Series B, in the amount of $18.75 per share (equivalent to $0.46875 per Depositary Share).
  • A cash dividend on the company's 7.50% Non-Cumulative Preferred Stock, Series C, in the amount of $18.75 per share (equivalent to $0.46875 per Depositary Share).

The dividend on the company’s common stock will be payable on July 17, 2017 to shareholders of record as of July 3, 2017.  Each dividend on the company’s preferred stock will be payable on July 17, 2017 to shareholders of record as of July 1, 2017.

About National General Holdings Corp.

National General Holdings Corp., headquartered in New York City, is a specialty personal lines insurance holding company. National General traces its roots to 1939, has a financial strength rating of A- (excellent) from A.M. Best, and provides personal and commercial automobile, homeowners, umbrella, recreational vehicle, motorcycle, supplemental health, and other niche insurance products.

CONTACT: Investor Contact Christine Worley Director of Investor Relations Phone: 212-380-9462 Email: Christine.Worley@NGIC.com
Categories: State

Brookfield Residential Introduces Shutters, a Rare, New Single-Family Home Collection Coming to Edenglen in Ontario Ranch

8 May 2017 - 6:03pm

ONTARIO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Brookfield Residential continues its legacy of creating the best places to call home with Shutters at Edenglen, an exciting collection of beautiful new homes coming soon to Ontario Ranch. Set within the intimate and established Edenglen master-planned community, this new neighborhood will feature three distinctive single-family detached designs, including one highly desirable single-level floorplan. With prices anticipated from the $500,000s, these thoughtfully planned homes will be infused with contemporary style and comfortable living spaces spanning from approximately 2,371 to 2,937 square feet with three to five bedrooms, two to four baths and two-car to three-bay garages. Select floorplans will showcase a convenient downstairs master suite, a private den, and a smart second floor with bedrooms and a versatile bonus room. Outside, many homes will include larger yards that are perfect for parties or gardening, while the charming Edenglen setting provides great opportunities for fun with parks, sports courts, a pool, clubhouse and much more.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a82cdc7-8837-4340-a854-fd0f213e8753

Potential homebuyers interested in this rare new-home opportunity at Edenglen, which includes the benefit of competitive, lower overall property taxes, should register their interest today at www.BrookfieldSoCal.com.

“We’re thrilled to debut this beautiful new neighborhood in such a prominent and well-loved community like Edenglen,” said Mercedes Meserve, Vice President of Marketing for Brookfield Residential Southern California. “Shutters will be an extraordinary addition to the community and we encourage buyers to join the interest list now for the latest news and updates.”

As part of the vibrant community of Edenglen, Shutters’ setting offers year-round fun for the whole family, where natural beauty, scenic parks, great amenities and community events inspire activity and connection every day. Set amidst 75 scenic acres, homeowners have access to a number of recreational areas on-site, including the popular Pinheiro Park, which features a clubhouse with multi-purpose and game rooms, a sparkling swimming pool, tot lots, and two half-basketball courts. Residents can also enjoy several community parks that are enhanced by native citrus trees, stroll along the picturesque walking trail and take pets to the friendly dog park.

Shutters’ great location near the 15 and 60 freeways is an asset for commuters, while its proximity to the LA/Ontario International Airport is excellent for frequent air travelers. Shopping, dining and entertainment options include the nearby Eastvale Gateway, Archibald Ranch Town Center, Victoria Gardens and Citizens Bank Arena, which is just a short drive away. Residents can play 18-holes at the Whispering Lakes Golf Course and visit several area parks for additional leisure opportunities. 

Edenglen is located in Ontario Ranch, which is a visionary model for California Growth with a massive parks and trails system, new schools and independent sources of water.

Ontario Ranch, located within the city of Ontario, California, will span across 8,000+ acres and has been thoughtfully planned with attainably priced new neighborhoods, modern amenities and abundant recreation elements that are the foundation of a well-rounded lifestyle. The future Chaffey Park will be the centerpiece of Ontario Ranch, a sprawling open space with parks and trails for playing, walking and exploring the outdoors. It has been sensibly planned to align with the goals of the Healthy Ontario Initiative and its efforts to provide residents with opportunities to enrich their wellbeing. Ontario Ranch is envisioned as a mixed‐use area that will encompass residential neighborhoods, commercial facilities and recreational amenities. Proposed plans include retail and business space, along with nearly 1,000 acres dedicated to public open space, parks and schools. A convenient location offers direct access to the I-15 via the new connection at Cantu-Galleano Ranch Road. With the introduction of Ontario Ranch Road as well as the connection to the 60 Freeway via the newly improved Archibald Avenue, Ontario Ranch offers commuters easy access to major employment centers in LA, Riverside, San Bernardino and Orange counties. For more information visit www.OntarioRanch.com.

For more information on Shutters at Edenglen in Ontario Ranch, please visit www.BrookfieldSoCal.com.

Prices effective date of publication.

About Brookfield Residential (Southern California)

Brookfield Residential Southern California (Los Angeles and San Diego) a division of Brookfield Residential, is committed to being more than a homebuilder. We strive to create the best places to call home. The Brookfield Residential Southern California (Los Angeles and San Diego) team has the passion, the expertise and the local knowledge to craft homes and neighborhoods that speak to homebuyers at every stage of life. We are an award-winning homebuilder and industry leader with an exceptional reputation for quality, design, and customer service. Please visit www.BrookfieldSoCal.com for more information.

Brookfield Residential Properties Inc. is a leading land developer and homebuilder in North America. We entitle and develop land to create master-planned communities, sell lots to third-party builders, and operate our own home building division. We also participate in select, strategic real estate opportunities, including infill projects, mixed-use developments, and joint ventures. Further information is available at BrookfieldResidential.com.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

CONTACT: CONTACT: Brittany Duhs – BrittanyD@HayesMartin.com (949) 417-1799
Categories: State

About us | Advertise | Help | Privacy Policy | Subscriptions, RSS © 2009 The Progress News . All Rights Reserved .